A citation-based method for searching scientific literature

Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
Times Cited: 112



D Athauda, T Foltynie. Prog Neurobiol 2016
Times Cited: 146




List of shared articles



Times cited

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse model.
Yi-Qing Lv, Lin Yuan, Yan Sun, Hao-Wen Dou, Ji-Hui Su, Zhi-Pan Hou, Jia-Yi Li, Wen Li. Transl Neurodegener 2022
1

Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
Merve Uyar, Susanne Lezius, Carsten Buhmann, Monika Pötter-Nerger, Robert Schulz, Stephanie Meier, Christian Gerloff, Jens Kuhle, Chi-Un Choe. Mov Disord 2022
2


The role of nutrition on Parkinson's disease: a systematic review.
Vittorio Emanuele Bianchi, Laura Rizzi, Fahad Somaa. Nutr Neurosci 2022
0

Parkinson's Disease and Sugar Intake-Reasons for and Consequences of a Still Unclear Craving.
Julienne Haas, Daniela Berg, Anja Bosy-Westphal, Eva Schaeffer. Nutrients 2022
0

Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study.
H S Chung, J S Lee, J A Kim, E Roh, Y-B Lee, S-H Hong, J H Yu, N H Kim, H J Yoo, J A Seo,[...]. Diabetes Metab 2021
6

Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
Daniella Balduino Victorino, Mariana Nejm, Marcia Guimarães-Marques, Fulvio Alexandre Scorza, Carla Alessandra Scorza. Pharmaceut Med 2021
2

Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson's Disease in Women than in Men.
Carola Deischinger, Elma Dervic, Michaela Kaleta, Peter Klimek, Alexandra Kautzky-Willer. J Parkinsons Dis 2021
5

Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce. Mov Disord 2021
28

Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.
Carmen M Labandeira, Arturo Fraga-Bau, David Arias Ron, Ana Muñoz, Gema Alonso-Losada, Antonio Koukoulis, Jesus Romero-Lopez, Ana I Rodriguez-Perez. Front Neuroendocrinol 2021
5

Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease.
Santiago Pérez-Lloret, Daniel P Cardinali. Front Pharmacol 2021
10

Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
Eduardo de Pablo-Fernández, Robert Courtney, Alice Rockliffe, Steve Gentleman, Janice L Holton, Thomas T Warner. Neuropathol Appl Neurobiol 2021
3

Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study.
Almudena Sánchez-Gómez, Yesika Díaz, Talita Duarte-Salles, Yaroslau Compta, Maria José Martí. Parkinsonism Relat Disord 2021
5

Disease modifying therapies III: Novel targets.
Nirosen Vijiaratnam, Thomas Foltynie. Neuropharmacology 2021
3

Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors.
Kai-Jung Lin, Tzu-Jou Wang, Shang-Der Chen, Kai-Lieh Lin, Chia-Wei Liou, Min-Yu Lan, Yao-Chung Chuang, Jiin-Haur Chuang, Pei-Wen Wang, Jong-Jer Lee,[...]. Antioxidants (Basel) 2021
3

Diabetes, BMI, and Parkinson's.
Tom Foltynie, Dilan Athauda. Mov Disord 2020
5


Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease.
Samantha Molsberry, Kjetil Bjornevik, Katherine C Hughes, Zhongli Joel Zhang, Sarah Jeanfavre, Clary Clish, Brian Healy, Michael Schwarzschild, Alberto Ascherio. J Parkinsons Dis 2020
4

The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Julia L Y Cheong, Eduardo de Pablo-Fernandez, Thomas Foltynie, Alastair J Noyce. J Parkinsons Dis 2020
41

Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice.
Iara Pérez-Taboada, Samuel Alberquilla, Eduardo D Martín, Rishi Anand, Stefania Vietti-Michelina, Nchimunya N Tebeka, James Cantley, Stephanie J Cragg, Rosario Moratalla, Mario Vallejo. Mov Disord 2020
18


Peripheral insulin and amylin levels in Parkinson's disease.
Almudena Sánchez-Gómez, Gema Alcarraz-Vizán, Manel Fernández, Rubén Fernández-Santiago, Mario Ezquerra, Ana Cámara, Mònica Serrano, Anna Novials, Esteban Muñoz, Francesc Valldeoriola,[...]. Parkinsonism Relat Disord 2020
9

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Ruth Brauer, Li Wei, Tiantian Ma, Dilan Athauda, Christine Girges, Nirosen Vijiaratnam, Grace Auld, Cate Whittlesea, Ian Wong, Tom Foltynie. Brain 2020
45

Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus.
Diana Luz Juárez-Flores, Mario Ezquerra, Ïngrid Gonzàlez-Casacuberta, Aida Ormazabal, Constanza Morén, Eduardo Tolosa, Raquel Fucho, Mariona Guitart-Mampel, Mercedes Casado, Francesc Valldeoriola,[...]. Antioxidants (Basel) 2020
5


α-Synuclein promotes IAPP fibril formation in vitro and β-cell amyloid formation in vivo in mice.
Marija Mucibabic, Pär Steneberg, Emmelie Lidh, Jurate Straseviciene, Agnieszka Ziolkowska, Ulf Dahl, Emma Lindahl, Helena Edlund. Sci Rep 2020
14